DocGo reported second-quarter 2026 results that missed Wall Street expectations, with adjusted loss per share of $0.16 versus a forecast loss of $0.10 and revenue of $73.4 million versus $75.4 million expected. The stock fell 11.28% after hours to $0.63.
The company's revenue from medical transportation rose to a record $52.0 million, offsetting a decline in mobile health revenue. Non-migrant mobile health revenue rose 78% year over year, supported by remote patient monitoring and mobile phlebotomy.
Q2 Results
DocGo missed both earnings and revenue estimates, posting adjusted EPS of negative $0.16 and revenue of $73.42 million. The company also widened its full-year 2026 adjusted EBITDA loss guidance to $17 million to $22 million.
Outlook
Management expects to exit 2026 at about breakeven adjusted EBITDA run rate, with additional efficiency programs launching in late 2026 and early 2027. The company is also pushing into virtual care through a planned Hicuity Health acquisition.